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Data Source
SBP DBP TC TG HDL-C LDL-C Creatinine BMI Glucose Liese et al.1999. s1 1005 1005 
Observational Association
Urate -lipid phenotypes Leise et al. s1 Puddu et al. s2 Medalie et al. s4 Moriarty et al. Puddu et al. s2 Medalie et al. s4 Moriarty et al. s5 Fang et al. s3 Tomita et al. Puddu et al. s2 Medalie et al. s4 Moriarty et al. s5 Fang et al. s3 Tomita et al. The membrane-associated protein encoded by this gene is included in the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra-and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the White subfamily. Alternatively referred to as a breast cancer resistance protein, this protein functions as a xenobiotic transporter which may play a major role in multi-drug resistance. It likely serves as a cellular defense mechanism in response to mitoxantrone and anthracycline exposure. Significant expression of this protein has been observed in the placenta, which may suggest a potential role for this molecule in placenta tissue. Multiple transcript variants encoding different isoforms have been found for this gene. rs675209 6 RREB1/RR EB1 None RREB1: The protein encoded by this gene is a zinc finger transcription factor that binds to RAS-responsive elements (RREs) of gene promoters. It has been shown that the calcitonin gene promoter contains an RRE and that the encoded protein binds there and increases expression of calcitonin, which may be involved in Ras/Raf-mediated cell differentiation. Multiple transcript variants encoding several different isoforms have been found for this gene. LY86: May cooperate with CD180 and TLR4 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) and cytokine production. Important for efficient CD180 cell surface expression (By similarity) Binds to APOB mRNA and is probably responsible for docking the catalytic subunit, APOBEC1, to the mRNA to allow it to deaminate its target cytosine. The complex also protects the edited APOB mRNA from nonsense-mediated decay/ASAH2: Hydrolyzes the sphingolipid ceramide into sphingosine and free fatty acid at an optimal pH of 6.5-8.5. Acts as a key regulator of sphingolipid signaling metabolites by generating sphingosine at the cell surface. Acts as a repressor of apoptosis both by reducing C16-ceramide, thereby preventing ceramide-induced apoptosis, and generating sphingosine, a precursor of the antiapoptotic factor sphingosine 1phosphate. Probably involved in the digestion of dietary sphingolipids in intestine by acting as a key enzyme for the catabolism of dietary sphingolipids and regulating the levels of bioactive sphingolipid metabolites in the intestinal tract. Figure S1 . The distribution of plasma urate concentration in the UCLEB consortium data. Figure S2 . Power curves derived from analytical outcomes. The vertical lines represent the effect, estimated by each method, of plasma urate concentration on CHD risk, colour coded as legend. Figure S3 . Observational association between plasma urate concentration and relative risk of CHD in 17 prospective population-based cohorts. Summary estimates obtained by fixed-effects (FE) and random effects (RE) meta-analysis are presented. Adjustment: + age and sex; +++ age, sex, smoking and some additional risk factors (not specified by original author), ++++ as +++ with adjustment for pre-existing CHD. Apart from UCLEB (BWHHS) the data were obtained from Wheeler et al. 2005, s18 the order of studies mirrors that publication.. (Size of point markers is proportional to the inverse variance). W = Women, M = Men. Figure S4 . The association of individual SNPs and the 31 SNP instrument for plasma urate concentration with continuous phenotypes. (Error bars are 95%CI, SNP order is by magnitude of effect within a phenotype, and all effects are with respect to the urate raising allele). Significant association in the 31 SNP instrument is indicative of pleiotropy. Figure S5 . The association of individual SNPs and the 31 SNP instrument for plasma urate concentration with continuous phenotypes. (Error bars are 95%CI, SNP order is by magnitude of effect within a phenotype, and all effects are with respect to the urate raising allele). Significant association in the 31 SNP instrument is indicative of pleiotropy. Figure S6 . The association of the individual SNPs and the 31 SNP instrument for plasma urate concentration with blood pressure. (Error bars are 95%CI, SNP order is by magnitude of effect within a phenotype, and all effects are with respect to the urate raising allele). Significant association in the 31 SNP instrument is indicative of pleiotropy. Figure S7 . The association of the individual SNPs and the 31 SNP instrument for plasma urate concentration with binary phenotypes. (Error bars are 95%CI, SNP order is by magnitude of effect within a phenotype, and all effects are with respect to the urate raising allele). Significant association in the 31 SNP instrument is indicative of pleiotropy. Figure S8 . Funnel plot of individual IV beta estimates for SNPs in the instrument. The distribution about the point estimate is asymmetric suggesting there is an unmeasured net pleiotropic effect on the instrument. (Egger test for funnel plot symmetry P.value = 0.011). Figure S9 . Sensitivity tests. The assumed normal distribution (black) of the point estimate of the IV beta using the 31 SNP instrument with (B) and without (A) covariates. Similar for MR Egger regression(C). In each case the red curve is the empirical distribution of the IV beta estimated in 100 000 25 SNP instruments obtained by repeatedly excluding 6 SNPs at random. Figure S10 . Association of SNPs with plasma urate concentration and risk of coronary heart disease. Effect estimates are as figure 2 in the main paper except that in this figure all effect estimates have been adjusted to be relative to the urate raising allele of the SNP. This allows the Egger Mendelian randomisation to be represented in the same figure. Error bars are 95% CI in each dimension.
